The observed inhibition of canonical pathways immediately downstream of FLT3 [24] as well as the presence of well-characterized gene products whose mutation are involved in AML progression or relapse (e.g., NPM1, CEBPA, KRAS, PTPN11) [25], confirm the clinical relevance of our models. Here, KRAS is linked to acute myeloid leukemia.